Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/30329% above fair value
$57.88+0.40 (+0.70%)
Close on Nov 17, 2026Market cap $2.96BP/E 137.8Yield –
Vericel revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Vericel's revenue for the twelve months ending Jun 30, 2026 was $306.30M, up 23.0% year over year. For fiscal 2025 it was $276.26M, up 16.5% from the year before. Over ten years it grew 18.4% a year on average. The highest annual figure on record is $276.26M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $276.26M | +16.5% |
| FY2024 | Dec 31, 2024 | $237.22M | +20.1% |
| FY2023 | Dec 31, 2023 | $197.52M | +20.2% |
| FY2022 | Dec 31, 2022 | $164.37M | +5.2% |
| FY2021 | Dec 31, 2021 | $156.18M | +25.8% |
| FY2020 | Dec 31, 2020 | $124.18M | +5.4% |
| FY2019 | Dec 31, 2019 | $117.85M | +29.7% |
| FY2018 | Dec 31, 2018 | $90.86M | +42.1% |
| FY2017 | Dec 31, 2017 | $63.92M | +17.5% |
| FY2016 | Dec 31, 2016 | $54.38M | +6.3% |
| FY2015 | Dec 31, 2015 | $51.17M | +77.7% |
| FY2014 | Dec 31, 2014 | $28.80M | +151457.9% |
| FY2013 | Dec 31, 2013 | $19.00K | -9.5% |
| FY2012 | Dec 31, 2012 | $21.00K | -76.4% |
| FY2010 | Jun 30, 2010 | $89.00K | -51.1% |
| FY2009 | Jun 30, 2009 | $182.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $77.46M | +22.5% |
| Q1 FY2026 | Mar 31, 2026 | $68.43M | +30.1% |
| Q4 FY2025 | Dec 31, 2025 | $92.92M | +23.3% |
| Q3 FY2025 | Sep 30, 2025 | $67.50M | +16.6% |
| Q2 FY2025 | Jun 30, 2025 | $63.24M | +20.1% |
| Q1 FY2025 | Mar 31, 2025 | $52.60M | +2.6% |
| Q4 FY2024 | Dec 31, 2024 | $75.38M | +16.0% |
| Q3 FY2024 | Sep 30, 2024 | $57.91M | +27.0% |
| Q2 FY2024 | Jun 30, 2024 | $52.66M | +14.7% |
| Q1 FY2024 | Mar 31, 2024 | $51.28M | +25.0% |
| Q4 FY2023 | Dec 31, 2023 | $65.00M | +23.3% |
| Q3 FY2023 | Sep 30, 2023 | $45.58M | +18.2% |
| Q2 FY2023 | Jun 30, 2023 | $45.92M | +24.0% |
| Q1 FY2023 | Mar 31, 2023 | $41.02M | +13.7% |
| Q4 FY2022 | Dec 31, 2022 | $52.69M | +10.7% |
| Q3 FY2022 | Sep 30, 2022 | $38.55M | +11.7% |
| Q2 FY2022 | Jun 30, 2022 | $37.05M | -6.3% |
| Q1 FY2022 | Mar 31, 2022 | $36.07M | +4.4% |
| Q4 FY2021 | Dec 31, 2021 | $47.59M | +5.2% |
| Q3 FY2021 | Sep 30, 2021 | $34.51M | +7.0% |
| Q2 FY2021 | Jun 30, 2021 | $39.52M | +97.5% |
| Q1 FY2021 | Mar 31, 2021 | $34.57M | +29.6% |
| Q4 FY2020 | Dec 31, 2020 | $45.23M | +14.8% |
| Q3 FY2020 | Sep 30, 2020 | $32.26M | +5.8% |
| Q2 FY2020 | Jun 30, 2020 | $20.01M | -23.5% |
| Q1 FY2020 | Mar 31, 2020 | $26.68M | +22.3% |
| Q4 FY2019 | Dec 31, 2019 | $39.39M | +25.7% |
| Q3 FY2019 | Sep 30, 2019 | $30.50M | +35.6% |
| Q2 FY2019 | Jun 30, 2019 | $26.15M | +37.6% |
| Q1 FY2019 | Mar 31, 2019 | $21.81M | +21.0% |
| Q4 FY2018 | Dec 31, 2018 | $31.34M | +34.2% |
| Q3 FY2018 | Sep 30, 2018 | $22.48M | +57.7% |
| Q2 FY2018 | Jun 30, 2018 | $19.01M | +12.1% |
| Q1 FY2018 | Mar 31, 2018 | $18.03M | +92.6% |
| Q4 FY2017 | Dec 31, 2017 | $23.35M | 0.0% |
| Q3 FY2017 | Sep 30, 2017 | $14.26M | +30.5% |
| Q2 FY2017 | Jun 30, 2017 | $16.95M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.36M | – |
| Q4 FY2016 | Dec 31, 2016 | $23.35M | – |
| Q3 FY2016 | Sep 30, 2016 | $10.93M | – |
See a number that looks wrong?